Premium
Increased expression of microRNA‐155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity
Author(s) -
García–Rodríguez S.,
Arias–Santiago S.,
BlascoMorente G.,
OrgazMolina J.,
RosalVela A.,
Navarro P.,
MagroCheca C.,
MartínezLópez A.,
Ruiz J.C.,
Raya E.,
NaranjoSintes R.,
Sancho J.,
Zubiaur M.
Publication year - 2017
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13861
Subject(s) - microrna , medicine , psoriasis , peripheral blood mononuclear cell , pathogenesis , psoriasis area and severity index , mir 155 , real time polymerase chain reaction , immunology , biology , gene , genetics , in vitro
Background Micro RNA s (mi RNA s) gene expression regulators are altered in psoriasis suggesting their role in the pathogenesis. Objective To study expression changes of inflammation and toll‐like receptor ( TLR )‐related mi RNA s, mi RNA ‐155, let‐7i, mi RNA ‐21, mi RNA ‐146a and mi RNA ‐223 in peripheral mononuclear cells ( PBMC s) and mi RNA ‐21, mi RNA ‐146a and mi RNA ‐223 in plasma, from chronic plaque‐type psoriasis patients who were treatment‐naive or had undergone a washout period ( n = 11). Mi RNA s were evaluated at baseline and after 11 (9–12) months [median (25th–75th percentile range)] of methotrexate ( MTX ) or topical (betamethasone plus calcipotriene) treatment. Methods Mi RNA expression was analysed with quantitative real‐time reverse transcription–polymerase chain reaction. Matched controls were studied. Results Psoriasis patients presented, at baseline, increased expression of mi RNA ‐155, let‐7i, mi RNA ‐146a, mi RNA ‐21 and mi RNA ‐223 in PBMC s, plus mi RNA ‐21, mi RNA ‐146a and mi RNA ‐223 in plasma. Receiver‐operator characteristic ( ROC ) curve analysis and area under the curve ( AUC ) showed that expression of these mi RNA s have the potential to distinguish between psoriasis and controls. At baseline, mi RNA ‐155 expression in PBMC s correlated with Psoriasis Area Severity Index ( PASI ) [12 (8–14)] (Spearman r : 0.7140, P < 0.05) suggesting a role in psoriasis. After MTX or topical treatment, reduction in PASI was observed [87.5% (75–100)]; mi RNA ‐155 expression in PBMC s decreased; plasma mi RNA ‐21, mi RNA ‐146a and mi RNA ‐223 were down‐regulated. ROC analysis showed that mi RNA ‐155 expression in PBMC s from psoriasis patients have the potential to distinguish between patients' samples at baseline and after treatment ( AUC : 0.942, sensitivity: 0.91; specificity: 0.91 values; maximum likelihood ratio =10). After treatment, mi RNA ‐146a expression in PBMC s increased; mi RNA ‐155/mi RNA ‐146a ratio decreased, suggestive of a regulatory feedback; let‐7i expression decreased; mi RNA ‐21 and mi RNA ‐223 remained elevated. Conclusion In this exploratory study, psoriasis patients presented increased expression of mi RNA ‐155 in PBMC s that correlated with PASI and decreased with disease remission. Mi RNA ‐21, mi RNA ‐146a and mi RNA ‐223 in PBMC s and plasma were increased at baseline and differentially modulated, underscoring different roles of TLR ‐related mi RNA s in psoriasis.